Insmed | INSM - Selling And Administration Expenses

Stock Price
109.10
Daily Change
-6.52 -5.64%
Monthly
-23.59%
Yearly
60.16%
Q2 Forecast
99.25

Insmed reported $247.26M in Selling and Administration Expenses for its fiscal quarter ending in March of 2026.





Selling And Administration Expenses Change Date
BioMarin Pharmaceutical USD 258.28M 63.92M Mar/2026
Cytokinetics USD 104.9M 13.17M Mar/2026
DBV Technologies USD 3.63M 3.18M Sep/2025
Gilead Sciences USD 1.45B 326M Mar/2026
Heron Therapeutics USD 23.74M 605K Dec/2025
Insmed USD 247.26M 34.78M Mar/2026
Novartis USD 3.44B 132M Dec/2025
Regeneron Pharmaceuticals USD 647.7M 127.3M Mar/2026
Sarepta Therapeutics USD 54.03M 51.35M Mar/2026
Ultragenyx Pharmaceutical USD 88M 1000K Mar/2026
Vertex Pharmaceuticals USD 493.7M 6.7M Mar/2026